Ken Griffin Entrada Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,600 shares of TRDA stock, worth $112,574. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,600
Previous 4,800
79.17%
Holding current value
$112,574
Previous $76,000
94.74%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TRDA
# of Institutions
103Shares Held
28.9MCall Options Held
40.3KPut Options Held
4.1K-
Baker Bros. Advisors LP New York, NY4.87MShares$63.7 Million0.93% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$57.7 Million33.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$57.3 Million60.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.9MShares$38 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.08MShares$27.2 Million0.02% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $411M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...